MBD3: A Drug Target / Disease Biomarker (G53615)

Target Name: MBD3

NCBI ID: G53615

MBD3

MBD3: A Drug Target / Disease Biomarker

MBD3, or multidimensional browser data, is a drug target and a potential biomarker for various diseases, including cancer. Its name stands for Multiple Block Designator, which refers to its ability to identify and track multiple patterns in data.

MBD3 technology was first developed by the University of California, San Diego, in 2013. It has since been used to identify potential drug targets in a variety of diseases, including cancer, and has the potential to revolutionize the field of drug development.

One of the key benefits of MBD3 is its ability to identify patterns in data that are missed by traditional methods. This is because MBD3 uses a novel approach to analyzing data, which involves breaking it down into smaller, more manageable pieces and then analyzing each piece separately. This allows it to identify patterns that may be missed by other methods.

In addition to its ability to identify new drug targets, MBD3 also has the potential to serve as a biomarker. This is because its ability to identify patterns in data can be used to identify characteristics of disease that may be useful for the development of new treatments. For example, by analyzing data from patients with a particular type of cancer,MBD3 may be able to identify characteristics that are associated with a higher risk of treatment success, such as the presence of certain genes.

Another potential use of MBD3 is its ability to identify patterns in data that are associated with the development of certain diseases. For example, MBD3 may be able to identify patterns in data that are associated with the development of heart disease, which could then be used to identify potential drug targets for heart disease.

Overall, MBD3 has the potential to be a powerful tool for the development of new drugs and therapies. Its ability to identify patterns in data that are missed by traditional methods makes it an attractive potential drug target, and its potential as a biomarker could be used to identify new characteristics of disease that may be useful for the development of new treatments.

While more research is needed to fully understand the potential of MBD3, its early results are promising. In addition to its potential as a drug target and biomarker, MBD3 has the potential to revolutionize the field of data analysis and its ability to identify patterns in data could have a wide range of applications in many different fields.

Protein Name: Methyl-CpG Binding Domain Protein 3

Functions: Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:12124384, PubMed:16428440, PubMed:28977666). Acts as transcriptional repressor and plays a role in gene silencing (PubMed:10947852, PubMed:18644863). Does not bind to methylated DNA by itself (PubMed:12124384, PubMed:16428440). Binds to a lesser degree DNA containing unmethylated CpG dinucleotides (PubMed:24307175). Recruits histone deacetylases and DNA methyltransferases

The "MBD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets